PDCD1 and esophageal squamous cell carcinoma: JAB-3068 has the potential to reduce tumor burden by enhancing CD8+ antitumor immunity through cytotoxic T-cells, indicating possible therapeutic promise for NSCLC, CRC, and esophageal squamous cell carcinoma (ESCC) when used in combination with an anti-PD1 antibody.